ReviewThe oncologist2011

Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

Rodrigo Dienstmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.